Identication of miRNA affecting triple-negativebreast cancer using bioinformatics analysis strategies

سال انتشار: 1402
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 28

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

CGC01_073

تاریخ نمایه سازی: 29 آبان 1402

چکیده مقاله:

Introduction: Breast cancer (BC) is the most common causeof cancer-related deaths in women worldwide. It can be classifiedinto several subtypes, including triple-negative (TN) tumours,a subtype of breast cancer with high heterogeneity andinvasiveness and limited targeted therapies. The lack of significantdiagnostic and prognostic markers has led to the failureof early diagnosis of triple-negative breast cancer (TNBC). Inthis study, we sought to identify genes and regulatory miRNAassociated with TNBC that may provide new insights into genedysregulation in TNBC.Materials and Methods: We used a microarray dataset from approximately ۲۶۵ samples. Significant differentially expressedgenes (DEGs) between the TN and non-TN tumours were identifiedby using the GEO۲R tool. To discover the major genesin PPI networks, use the cytoHubba plugin in Cytoscape. Geneexpression profile interaction analysis (GEPIA) was used toconfirm the expression of hub genes regulatory microRNA ofthe identified hub gene were provided by targetscan, mirbase,mirwalk, mirable software.Result: The analysis of GSE۷۶۲۷۵ showed that out of ۵۴,۶۷۶differentially expressed genes (p‐value<۰.۰۱), ۶۳ up-regulatedand ۱۶۴ down-regulated genes were identified with a log foldchange higher and lower or equal to | ۱.۵ |. Based on the PPInetwork, NUF۲, ANLN and TYMS play key roles in the progressionof TN tumours. Our study confirmed that the NUF۲hub gene is regulated by the down-expression of hsa-mir-۱۹۶b-۳p and hsa-mir-۲۹b-۲-۵p regulates the ANLN gene, compareTN tumours and non- TN tumours.Conclusion: This study offers, further in vitro assays is necessaryto confirm our findings

نویسندگان

Samira behroozi

Department of Medical Genetics, National Institute of GeneticEngineering and Biotechnology (NIGEB), Tehran, Iran

mahdieh salimi

Department of Medical Genetics, National Institute of GeneticEngineering and Biotechnology (NIGEB), Tehran, Iran

najaf allahyari fard

Department of Systems Biotechnology, National Institute of GeneticEngineering and Biotechnology (NIGEB), Tehran, Iran.

Mitra ataei

Department of Medical Genetics, National Institute of GeneticEngineering and Biotechnology (NIGEB), Tehran, Iran